Filtering by content type: Public Statement
(The Role of the Commission, Congress, and the Courts)
(Health Care as the New Cement; and Actions Against the Pharmaceutical Industry as a Game of Whack-a-Mole)
This article is a written version of a speech given at a forum on Antitrust and Health Care jointly sponsored by the Health Lawyers Association and the ABA Sections of Antitrust Law and Health Law (May 15, 2003), and is published in Antitrust, Spring 2004, Volume 18, No. 2, at 23.
This is an interview with Commissioner Leary conducted by the ABA Antitrust Section Health Care Committee Newsletter, published in the ABA's Antitrust Health Care Chronicle, October 2005, Vol. 19, No. 3.
This article is based on a speech delivered at the Saint Louis University Health Law Symposium on April 12, 2002, and is published in issue 47:2 of the Saint Louis University Law Journal, at page 217.
It is an honor to be here and join such an impressive group of practitioners, government officials, judges, academics and economists to discuss the cutting edge issues confronting health care and antitrust.
Good afternoon. Thank you for the opportunity to address the 30th Annual Antitrust Institute on Healthcare Antitrust Developments on what is a very interesting and exciting topic. Let me say before I begin that the views I express are entirely my own and do not necessarily represent the views of...
Good afternoon. It is a pleasure to be here today to discuss the antitrust analysis of physician networks and other integrated delivery systems. As always, I must remind you that my remarks today reflect only my own views and are not necessarily those of the Commission or of any other Commissioner.
Good morning. It is a pleasure to be here today to introduce this morning's program on the antitrust analysis of hospital mergers, HMO mergers and physician networks. I would like to express my sincere thanks to General Burson for his kind introductory remarks and for hosting this conference. As...
Mr. Chairman, the Federal Trade Commission thanks you and the members of the Committee for inviting us again this year to present the Commission's views on a proposed antitrust exemption to allow physicians and other health care professionals to engage in collective bargaining with health plans.
As the title indicates, the settlement of pharmaceutical patent disputes is a subject that I have already addressed.(1) You may wonder why I am visiting it again. When I first discussed the issue last November, The Federal Trade Commission ("the Commission") had brought only two cases,(2) with a...
The views presented are those of author and do not necessarily represent those of the Bureau of Competition, or any individual Commissioner.